Eliana Rulli1, Lorenzo Legramandi1, Lorenzo Salvati2, Mario Mandala3. 1. Department of Oncology, Mario Negri IRCCS Institute for Pharmacological Research, Milan, Italy. 2. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. 3. Unit of Medical Oncology, Department of Oncology and Hematology, Pope John XXIII Cancer Center Hospital, Bergamo, Italy.
Abstract
BACKGROUND: Targeted therapies (TT), combination immunotherapy (CMI), and monoimmunotherapy (MI) in combination with radiotherapy (CRI) or not are commonly used in patients with melanoma brain metastases, but studies that directly compare these strategies are lacking. The current meta-analysis aimed to better elucidate their activity and efficacy. METHODS: A systematic search of MEDLINE, Embase, and conference proceedings up to January 2019 was performed to identify trials investigating combination TT, monotargeted TT (mono TT), MI, CMI, and CRI in melanoma brain metastases. The outcomes considered were progression-free survival (PFS), overall survival (OS), and the objective response rate (ORR) as evaluated at both intracranial and extracranial sites. Random effects models were used to compare the different therapeutic strategies. RESULTS: A total of 15 trials were included that provided 1132 patients for analyses. CMI demonstrated a statistically significant better OS compared with MI (P = .03, P = .05, and P = .03, respectively, at 6 months, 18 months, and 24 months) and combination TT (P = .04 and P = .03, respectively, at 18 months and 24 months). CMI demonstrated a statistically significant better PFS compared with combination TT (P < .001 at 12 months and 18 months), MI (P = .02, P < .02, and P = .05, respectively, at 6 months, 12 months, and 18 months), and mono TT (P < .001 at 6 months, 12 months, and 18 months). The intracranial objective response rate was higher with CMI compared with mono TT (P < .001) and MI (P < .001), whereas there was no difference between CMI and combination TT. CONCLUSIONS: The results of the current meta-analysis suggested that CMI increases long-term PFS and OS compared with MI and combination TT. Combination TT and CMI are associated with a similar intracranial response rate. The role of systemic therapy in combination with radiotherapy remains to be better elucidated.
BACKGROUND: Targeted therapies (TT), combination immunotherapy (CMI), and monoimmunotherapy (MI) in combination with radiotherapy (CRI) or not are commonly used in patients with melanoma brain metastases, but studies that directly compare these strategies are lacking. The current meta-analysis aimed to better elucidate their activity and efficacy. METHODS: A systematic search of MEDLINE, Embase, and conference proceedings up to January 2019 was performed to identify trials investigating combination TT, monotargeted TT (mono TT), MI, CMI, and CRI in melanoma brain metastases. The outcomes considered were progression-free survival (PFS), overall survival (OS), and the objective response rate (ORR) as evaluated at both intracranial and extracranial sites. Random effects models were used to compare the different therapeutic strategies. RESULTS: A total of 15 trials were included that provided 1132 patients for analyses. CMI demonstrated a statistically significant better OS compared with MI (P = .03, P = .05, and P = .03, respectively, at 6 months, 18 months, and 24 months) and combination TT (P = .04 and P = .03, respectively, at 18 months and 24 months). CMI demonstrated a statistically significant better PFS compared with combination TT (P < .001 at 12 months and 18 months), MI (P = .02, P < .02, and P = .05, respectively, at 6 months, 12 months, and 18 months), and mono TT (P < .001 at 6 months, 12 months, and 18 months). The intracranial objective response rate was higher with CMI compared with mono TT (P < .001) and MI (P < .001), whereas there was no difference between CMI and combination TT. CONCLUSIONS: The results of the current meta-analysis suggested that CMI increases long-term PFS and OS compared with MI and combination TT. Combination TT and CMI are associated with a similar intracranial response rate. The role of systemic therapy in combination with radiotherapy remains to be better elucidated.
Authors: Assaf Berger; Kenneth Bernstein; Juan Diego Alzate; Reed Mullen; Joshua S Silverman; Erik P Sulman; Bernadine R Donahue; Anna C Pavlick; Jason Gurewitz; Monica Mureb; Janice Mehnert; Kathleen Madden; Amy Palermo; Jeffrey S Weber; John G Golfinos; Douglas Kondziolka Journal: J Neurooncol Date: 2022-06-04 Impact factor: 4.130
Authors: Anna-Katharina Meißner; Robin Gutsche; Norbert Galldiks; Martin Kocher; Stephanie T Jünger; Marie-Lisa Eich; Manuel Montesinos-Rongen; Anna Brunn; Martina Deckert; Christina Wendl; Wolfgang Dietmaier; Roland Goldbrunner; Maximilian I Ruge; Cornelia Mauch; Nils-Ole Schmidt; Martin Proescholdt; Stefan Grau; Philipp Lohmann Journal: Neuro Oncol Date: 2022-08-01 Impact factor: 13.029
Authors: Hussein A Tawbi; Peter A Forsyth; F Stephen Hodi; Alain P Algazi; Omid Hamid; Christopher D Lao; Stergios J Moschos; Michael B Atkins; Karl Lewis; Michael A Postow; Reena P Thomas; John Glaspy; Sekwon Jang; Nikhil I Khushalani; Anna C Pavlick; Marc S Ernstoff; David A Reardon; Ragini Kudchadkar; Ahmad Tarhini; Caroline Chung; Corey Ritchings; Piyush Durani; Margarita Askelson; Igor Puzanov; Kim A Margolin Journal: Lancet Oncol Date: 2021-11-10 Impact factor: 54.433
Authors: Archya Dasgupta; Jayson Co; Jeff Winter; Barbara-Ann Millar; Normand Laperriere; Derek S Tsang; Monique van Prooijen; Andrei Damyanovich; Robert Heaton; Catherine Coolens; Mark Bernstein; Paul Kongkham; Gelareh Zadeh; Alejandro Berlin; Tatiana Conrad; Fabio Y Moraes; David B Shultz Journal: Curr Oncol Date: 2021-01-18 Impact factor: 3.677
Authors: Alexander F C Hulsbergen; Abdullah M Abunimer; Fidelia Ida; Vasileios K Kavouridis; Logan D Cho; Ishaan A Tewarie; Rania A Mekary; Philippe Schucht; John G Phillips; Joost J C Verhoeff; Marike L D Broekman; Timothy R Smith Journal: Neuro Oncol Date: 2021-12-01 Impact factor: 13.029
Authors: Teresa Amaral; Felix Kiecker; Sarah Schaefer; Henner Stege; Katharina Kaehler; Patrick Terheyden; Anja Gesierich; Ralf Gutzmer; Sebastian Haferkamp; Jochen Uttikal; Carola Berking; David Rafei-Shamsabadi; Lydia Reinhardt; Friedegund Meier; Ante Karoglan; Christian Posch; Thilo Gambichler; Claudia Pfoehler; Kai Thoms; Julia Tietze; Dirk Debus; Rudolf Herbst; Steffen Emmert; Carmen Loquai; Jessica C Hassel; Frank Meiss; Thomas Tueting; Vanessa Heinrich; Thomas Eigentler; Claus Garbe; Lisa Zimmer Journal: J Immunother Cancer Date: 2020-03 Impact factor: 13.751
Authors: Laurens V Beerepoot; Patrick E J Hanssens; Niels J van Ruitenbeek; Vincent K Y Ho; Hans M Westgeest Journal: J Neurooncol Date: 2021-06-25 Impact factor: 4.130